Sinopharm Group Co ( (HK:1099) ) has provided an announcement.
Sinopharm Accord reported a slight decrease in revenue for 2024, down 1.46% to RMB74.378 billion. The company’s net profit attributable to shareholders fell significantly by 59.83% to RMB642 million, indicating challenges in maintaining profitability despite a slight increase in net assets. The financial results reflect a substantial decline in operating and total profits, impacting the company’s return on equity and earnings per share.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the pharmaceutical industry, focusing on the distribution and retail of pharmaceuticals and medical devices. It is a major player in the Chinese market, with its subsidiary Sinopharm Accord listed on the Shenzhen Stock Exchange.
YTD Price Performance: -19.78%
Average Trading Volume: 2,115
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.44B
For detailed information about 1099 stock, go to TipRanks’ Stock Analysis page.